Patient characteristics
| Characteristic . | ATG + CyA . | ATG + CyA + G-CSF . | P . |
|---|---|---|---|
| No. of patients randomized | 50 | 51 | — |
| No. of patients evaluable | 47 | 48 | — |
| Age, median y (range) | 54 (19-75) | 53 (19-74) | .55 |
| Sex, male/female | 21/26 | 23/25 | .75 |
| Cause of AA, no. patients | |||
| Idiopathic | 46 | 46 | .51 |
| Hepatisis | 1 | 2 | — |
| Hemoglobin, median g/L (range) | 60 (35-82) | 60 (31-84) | .67 |
| Neutrophil count, median × 109/L (range) | 0.32 (0.02-1.01) | 0.30 (0.01-1.21) | .45 |
| Platelet count, median × 109/L (range) | 9 (1-38) | 9 (1-31) | .62 |
| Reticulocyte count, median × 109/L (range) | 11 (0-65) | 9 (0-35) | .08 |
| No. of patients with a neutrophil count less than 0.2 × 109/L | 11 | 19 | .07 |
| Interval between diagnosis and treatment, median d (range) | 20 (3-152) | 18 (1-112) | .89 |
| Characteristic . | ATG + CyA . | ATG + CyA + G-CSF . | P . |
|---|---|---|---|
| No. of patients randomized | 50 | 51 | — |
| No. of patients evaluable | 47 | 48 | — |
| Age, median y (range) | 54 (19-75) | 53 (19-74) | .55 |
| Sex, male/female | 21/26 | 23/25 | .75 |
| Cause of AA, no. patients | |||
| Idiopathic | 46 | 46 | .51 |
| Hepatisis | 1 | 2 | — |
| Hemoglobin, median g/L (range) | 60 (35-82) | 60 (31-84) | .67 |
| Neutrophil count, median × 109/L (range) | 0.32 (0.02-1.01) | 0.30 (0.01-1.21) | .45 |
| Platelet count, median × 109/L (range) | 9 (1-38) | 9 (1-31) | .62 |
| Reticulocyte count, median × 109/L (range) | 11 (0-65) | 9 (0-35) | .08 |
| No. of patients with a neutrophil count less than 0.2 × 109/L | 11 | 19 | .07 |
| Interval between diagnosis and treatment, median d (range) | 20 (3-152) | 18 (1-112) | .89 |
— indicates not applicable.